February 21, 2023 10:48 AM ESTUpdated February 24, 04:15 AM
FDA+

Al­ny­lam gets an ad­comm for On­pat­tro treat­ment in AT­TR amy­loi­do­sis

Tyler Patchen

News Reporter

Al­ny­lam Phar­ma­ceu­ti­cals is hop­ing its lat­est round of da­ta for On­pat­tro’s treat­ment of AT­TR is enough to sat­is­fy the FDA. But they’ll have to make …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times